Syros Pharmaceuticals Inc (NASDAQ:SYRS) Has Decline in Shorts

July 13, 2018 - By Darrel Chase

The stock of Syros Pharmaceuticals Inc (NASDAQ:SYRS) registered a decrease of 12.53% in short interest. SYRS’s total short interest was 1.36 million shares in July as published by FINRA. Its down 12.53% from 1.56M shares, reported previously. With 129,000 shares average volume, it will take short sellers 11 days to cover their SYRS’s short positions. The short interest to Syros Pharmaceuticals Inc’s float is 8.98%.

The stock decreased 0.24% or $0.03 during the last trading session, reaching $12.34. About 41,999 shares traded. Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has declined 14.15% since July 13, 2017 and is downtrending. It has underperformed by 26.72% the S&P500.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing treatments for cancer and immune-mediated diseases, and building a pipeline of gene control medicines. The company has market cap of $402.02 million. The Company’s lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. It currently has negative earnings. The firm was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.

More important recent Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) news were published by: which released: “56 Biggest Movers From Yesterday” on June 22, 2018, also published article titled: “Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17 …”, published: “2 Stable and 2 Speculative Biotech Stocks to Buy” on June 15, 2018. More interesting news about Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) was released by: and their article: “Syros Announces Appointment of Michael W. Bonney to Its Board of Directors” with publication date: June 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.